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Abstract
Pemphigus is a chronic autoimmune condition that can afect multiple areas of the body. The two main subtypes of pemphi-
gus are pemphigus vulgaris (PV) and pemphigus foliaceus (PF) which can rarely occur concurrently or even transition from 
one to the other. The process of transition may be explained by qualitative changes in desmoglein autoantibody proile. We 
present a rare case of concomitant PF and oral PV and explore the literature on transitions between pemphigus subtypes 
and whether this case could represent a transition from PF to PV. Furthermore, the realities of multidisciplinary patient 
management are discussed.
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Introduction
Pemphigus is a rare autoimmune mucocutaneous blistering 
condition with four variants; pemphigus vulgaris, pemphi-
gus foliaceus, IgA pemphigus and paraneoplastic pemphi-
gus. These all difer in their histological features and target 
antigens [1]. The two major types are pemphigus vulgaris 
(PV) and pemphigus foliaceus (PF) [2]. Histologically both 
are characterised by suprabasal acantholysis, however in PV 
this occurs in the lower third of the epithelium/epidermis 
whereas in PF it occurs in the upper third of the epider-
mis [2, 3]. This acantholysis is as a result of circulating 
autoantibodies targeting desmosomal cadherins within des-
mosomes that bind epithelial cells together [2, 4].
PV targets desmosomal cadherins named desmoglein 3 
(Dsg3) and desmoglein 1 (Dsg1) whereas PF targets Dsg1 
only. Dsg3 and Dsg1 display diferent expression patterns 
within mucosa and skin which inluences the distribution 
of blistering [5, 6] (Fig. 1). In mucosa, Dsg3 is expressed 
highly throughout the entire epithelium, whereas Dsg1 is 
expressed in much lower amounts and mainly in the super-
icial layers. Conversely, in skin, there is only a low amount 
of Dsg3 which is expressed in the basal and parabasal layers 
only, whereas Dsg1 is expressed throughout the entire epi-
dermis and particularly highly in the supericial layers [5–7].
The method by which these difering expression patterns 
afects the distribution of blisters is explained by the ‘Dsg 
compensation theory’ [5–8]. PF has only anti-Dsg1 autoan-
tibodies, therefore in the mucosa the presence of Dsg3 can 
compensate for the loss of Dsg1 and no blisters are formed. 
In the skin, the presence of Dsg3 in the lower third of the 
epidermis can similarly compensate, however there is no 
Dsg3 in the upper third of the epidermis hence there is blis-
ter formation here [5–8]. Therefore, in PF, the oral mucosa 
is unafected and blistering commonly afects the skin of 
the trunk, scalp and face [3, 4, 9, 10]. In the later stages of 
PV, both anti-Dsg1 and anti-Dsg3 autoantibodies can be dis-
played, and as a result no compensation can occur resulting 
in blisters afecting both mucosa and skin [5–8]. Therefore, 
in PV, blistering can afect the oral cavity, skin, pharynx, 
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larynx, conjunctiva, oesophagus and anogenital region [4, 
9, 10].
A literature search using Pubmed, Ovid and Web of Sci-
ence revealed a very limited number of cases of concomitant 
PF and oral PV. We also reviewed the literature regarding 
transitions between pemphigus subtypes. Therefore, the aim 
of this case report is to demonstrate the management of a 
rare case of PF and oral PV and discuss whether it represents 
a rare transition from PF to PV.
Case Report
A 53-year-old male was referred to the Oral Medicine 
Department by Dermatology in July 2008, with an 8-month 
history of blistering and soreness of the oral mucosa. On 
examination, there were small erosions and ulcers present 
on the soft palate and bilaterally on the buccal mucosae. 
The patient had been under the care of Dermatology since 
2003 for an itchy rash on the legs, scalp and chest. A biopsy 
from a crusted lesion on the scalp (Fig. 2) in 2003 revealed 
acantholysis of the keratinocytes in the upper part of the 
prickle cell layer (Fig. 3), and direct immunoluorescence 
studies showed IgG positivity around the upper epidermal 
cells. These features were consistent with a diagnosis of PF. 
He was started on Mycophenolate Mofetil (MMF) 500 mg 
twice a day and Prednisolone 10 mg once a day by Derma-
tology in 2006, which had resulted in excellent control of 
his cutaneous lesions. Prior to this, Azathioprine alone had 
been introduced on two occasions by Dermatology, however 
the patient failed to tolerate it due to nausea and vomiting. 
Oral involvement only began in January 2008 which required 
hospital admission for a short period.
His only other relevant medical history was hypertension, 
for which he took Nifedipine. At initial presentation, he was 
also taking Ranitidine and Alendronic Acid for protection 
against osteoporosis with prolonged systemic corticosteroid 
use. He was a non-smoker and had low alcohol intake.
At initial appointment, MMF dose was increased to 1 g 
in the morning and 500 mg in the evening for 2 weeks, and 
thereafter 1 g twice a day. Full blood count, urea and elec-
trolytes and liver function tests were normal, and regular 
blood monitoring was carried out appropriately. In light of 
good response to systemic therapy and as only very small 
erosions/ulcers were present at this point, oral biopsy was 
not arranged. He was seen regularly on the joint Oral Medi-
cine/Dermatology clinic and complete resolution of the oral 
lesions had occurred 5 months later. MMF 1 g twice a day 
was continued, however the Prednisolone dose was gradually 
reduced before being stopped. After ceasing Prednisolone, 
the patient developed an itchy dry patch of skin on the fore-
inger of his right hand. This was assessed by a consultant 
Fig. 1  Distribution of Dsg1 and Dsg3 in mucosa and skin. In mucosa, 
Dsg3 is expressed highly throughout the entire epithelium, whereas 
Dsg1 is expressed in much lower amounts and mainly in the super-
icial layers. Conversely, in skin, there is only a low amount of Dsg3 
which is expressed in the basal and parabasal layers only, whereas 
Dsg1 is expressed throughout the entire epidermis and particularly 
highly in the supericial layers [5, 6]
Fig. 2  Crusted lesions on the scalp with histological diagnosis of PF
Fig. 3  Histological image of skin from the scalp showing acantholy-
sis in the upper third of the epidermis in PF (×20 magniication Hae-
matoxylin & Eosin)
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Dermatologist who clinically diagnosed Lichen Simplex 
Chronicus and advised him to use Elocon (Mometasone) 
cream.
In 2010, the patient reported a lare in cutaneous symp-
toms, including scalp and genital discomfort. On examina-
tion, there were crusted lesions on the scalp. Wickham striae 
and erosions were seen on the glans penis (Fig. 4), there-
fore genital erosive lichen planus was clinically diagnosed 
by a consultant Dermatologist. There were also skin lesions 
on the arms and legs clinically resembling lichen planus. 
Oral lesions, more signiicant than seen previously, were 
also noted at this appointment. These consisted of an ulcer 
on the soft palate and an erosion in the left buccal mucosa 
(Fig. 5). MMF dose was increased and incisional biopsies 
of the buccal mucosa for histopathology and direct immuno-
luorescence were organised. This revealed intra-epithelial 
separation between prickle and basal cell layers (Fig. 6), and 
positive staining for IgG in the lower third of the epithelium. 
The features were consistent with a diagnosis of PV.
The patient proceeded to have well controlled oral PV, 
however problematic PF of the scalp which was managed 
with Xamiol gel (calcipotriol and betamethasone diproprion-
ate) and Etrivex shampoo (clobetasol proprionate). The dose 
of MMF has varied depending on symptoms and currently 
the skin, oral mucosa and genitals are stable on MMF 1 g in 
the morning and 500 mg in the evening.
Discussion
A literature search using Pubmed, Ovid and Web of Science 
using the search terms ‘pemphigus vulgaris’ and ‘pemphi-
gus foliaceus’ and ‘coexisting’ or ‘coexistence’, as well as a 
second search using the search terms ‘pemphigus’ and ‘vul-
garis’ and ‘foliaceus’ revealed a limited number of cases of 
concomitant PV and PF. A total of 8 papers were identiied 
(with a total of 17 patients), however only 3 of these papers 
(5 patients) showed patients with both cutaneous and oral 
mucosal involvement [2, 11, 12]. The remaining papers 
involved patients with cutaneous lesions only [13–16], with 
one describing a case of concurrent PV and PF of the nose 
[17]. Of the three papers describing both cutaneous and oral 
mucosal involvement, only Komai et al. [2] demonstrated a 
histological diagnosis of both PV and PF in three patients. 
The other two papers only had a histological diagnosis of 
PV, with the diagnosis of PF being made clinically [11, 12]. 
This makes our case particularly novel.
Transitions between the two pemphigus subtypes are 
a known phenomenon and therefore, it could be possible 
that a transition from PF to PV has occurred in our patient 
[2, 10, 18–20]. The process of transition may be explained 
by qualitative changes in desmoglein autoantibody proile 
[2, 18]. Exactly how this occurs is not fully known, how-
ever one proposed mechanism is epitope spreading [2, 21]. 
Fig. 4  Wickham striae and erosions on the glans penis, characteristic 
of erosive LP
Fig. 5  Erosion on the buccal mucosa with histological diagnosis of 
PV
Fig. 6  Histological image of buccal mucosa showing acantholysis in 
the lower third of the epithelium in PV (×20 magniication Haema-
toxylin & Eosin)
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An epitope is the part of an antigen molecule to which an 
antibody attaches itself. In epitope spreading, the primary 
autoimmune response leads to tissue damage which causes 
a new epitope to be revealed, hence provoking a secondary 
autoimmune response [21, 22]. Epitope spreading can occur 
both within the same protein (intramolecular) (Fig. 7) and 
between distinct proteins within the same tissue (intermo-
lecular) [5, 21]. PV is an example of both intramolecular 
and intermolecular epitope spreading (Fig. 8); in the earlier 
stages of the disease, patients tend to only display mucosal 
lesions but often progress to mucocutaneous involvement. 
This suggests that intermolecular epitope spreading has 
occurred from Dsg3 to Dsg1 and, as described previously, 
when both Dsg1 and Dsg3 are present no compensation 
can occur which results in blister formation in both mucosa 
and skin. In the initial stages of PV, when only anti-Dsg3 
autoantibodies are present, the presence of Dsg1 through-
out the entire epidermis compensates for the loss of Dsg3 
in the basal layers and the skin is spared. However, in the 
mucosa, Dsg1 is present in too low amounts to compensate, 
and mucosal blisters occur [5–8].
With regards to intramolecular epitope spreading in 
PV (Fig. 7), it is suggested that in the two disease stages 
(mucosal PV and mucocutaneous PV) the Dsg3 autoantibod-
ies recognise diferent Dsg3 epitopes. Speciically, studies 
have shown that Dsg3 autoantibodies in mucosal PV do not 
bind to human skin in indirect immunoluorescence however 
in mucocutaneous PV they do [5, 25]. The secondary Dsg3 
epitope is present in skin and shows homology with Dsg1 
[5, 21]. It has been demonstrated that this Dsg3 intramolecu-
lar epitope spreading precedes the intermolecular epitope 
spreading from Dsg3 to Dsg1 [5] (Fig. 8). In the case of PF 
transforming to PV, it may be that autoantibodies to Dsg1 
only are originally present, but the tissue damage to the skin 
causes ‘hidden’ Dsg3 to be ‘revealed’ to the immune system, 
provoking the production of autoantibodies to Dsg3 [10, 21, 
26]. Epitope spreading occurs in several other autoimmune 
skin diseases, including epidermolysis bullosa acquisita, bul-
lous pemphigoid, lichen planus pemphigoides and systemic 
lupus erythematosus [21].
Transitions between PF and PV are rare; a literature 
search using Pubmed, Ovid and Web of Science using 
the search terms ‘pemphigus foliaceus’ and ‘pemphigus 
vulgaris’ and ‘transition’ or ‘shift’ revealed a total of 19 
relevant papers describing 24 cases of PV to PF transi-
tion, and only 6 cases of PF to PV transition. One case 
transitioned from PV to PF and then back to PV [2]. Of 
these 19 papers, 16 (equaling 26 transition cases) used 
either immunoblotting, enzyme-linked immunosorbent 
Fig. 7  Diagram of intramolecular epitope spreading. An antigen has 
multiple epitopes (diferent coloured boxes). The antigen is processed 
by an antigen presenting cell (APC) and one fragment (blue square) 
is presented to a T-helper cell (Th1 cell). The Th1 cell releases 
cytokines which stimulates a B cell to produce antibodies and express 
antigen speciic immunoglobulins on the cell surface. Surface immu-
noglobulin then recognises the intact antigen and it is processed by 
the B cell acting as an APC. A new epitope (red square) is then pre-
sented to a Th1 cell with a diferent antigen speciicity. This initiates 
the production of diferent antibodies to a new epitope of the same 
antigen [23]
Fig. 8  Epitope spreading in PV. 
The primary immune response 
from the initiating Dsg epitope 
(blue circle) can cause diferent 
Dsg3 epitopes (red and green 
circles) within the same protein 
to be exposed; this is known 
as intramolecular epitope 
spreading. In PV, this precedes 
intermolecular spreading where 
Dsg1 epitopes in a diferent pro-
tein are exposed (yellow square) 
and hence cutaneous lesions 
occur. [5, 24]
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assay (ELISA) or both, to detect autoantibodies and 
confirm shifts between Dsg1 and Dsg3 [2, 10, 13, 20, 
27–30]. Both techniques are used to identify target pro-
teins, however, studies have shown ELISA to be more 
highly specific and sensitive for detecting autoantibodies 
in the sera of patients with PF and PV [2, 31–34]. PF 
sera only reacts with Dsg1 whereas PV sera can react 
with both Dsg1 and Dsg3 [2]. Unfortunately ELISA or 
immunoblotting was not used in our patient; therefore, it 
is difficult to confirm if a true transition from PF to PV 
has occurred. However, as PF only targets Dsg1, and sub-
sequently the patient developed lesions in the oral mucosa 
(which predominantly contains Dsg3) [4, 9, 10], there is 
evidence of a shift in autoantibody profile. It may be the 
case that if a repeat biopsy from the scalp was performed, 
it would reveal PV; however, there is no clinical justifica-
tion to do so currently as it would not change the patient 
management.
It is interesting that in addition to PF and oral PV the 
patient was also clinically diagnosed with genital lichen 
planus. Unfortunately, there is no histological confirma-
tion of this diagnosis, as biopsy was not deemed to be 
warranted due to the characteristic clinical features of 
the glans penis and because the result would not alter 
our current management. Therefore, it could be that the 
genital lesions in fact represent genital PV, especially 
given that the oral lesions also have a clinically lichenoid 
appearance (Fig. 4). Furthermore, within the PV buccal 
mucosa biopsy there was a distinct area of hyperkera-
tosis with an associated band-like infiltrate resembling 
a lichenoid tissue reaction, however the significance of 
this is unknown. Interestingly, within the literature there 
are cases of oral lichen planus with circulating anti-Dsg3 
antibodies, which are typically characteristic of PV [35, 
36]. The pathogenic role of these antibodies in lichen 
planus however, is not yet understood.
Regarding management, it was crucial that a multidis-
ciplinary approach was taken; hence the patient is seen 
regularly on the joint Oral Medicine/Dermatology clinics. 
Treatment has been tailored to both the patient’s oral and 
cutaneous symptoms, with one of the main challenges 
being reaching a stable dose of MMF appropriate for all 
aspects of the patient’s condition. Over the past 9 years, 
the dose has varied from 500 mg twice a day to 1.5 g 
twice a day, with various combinations in between. With 
these regular dose alterations, it has been vital to ensure 
that appropriate blood monitoring has been adhered to 
prevent side effects such as neutropenia and leucopenia 
[37]. With the patient travelling a significant distance to 
our clinic, this has required close liaison and a shared care 
protocol with the General Medical Practitioner.
Conclusion
This case report describes an interesting and rare case of 
concomitant PF and oral PV. It is possible that this rep-
resents an uncommon case of transition from PF to PV, 
however without conirmation with ELISA or immunoblot-
ting, a true transition is diicult to conirm. The process of 
transition may be explained by the mechanism of epitope 
spreading, which occurs in other autoimmune skin diseases. 
It is essential that patients with mucocutaneous conditions 
are managed with a multidisciplinary approach and tailored 
therapy.
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